Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eszopiclone + fluoxetine
- Development stage
- Phase 4
- Lead developer
- Sunovion
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Eszopiclone + fluoxetine is a combination therapy involving two small molecule drugs: eszopiclone, a nonbenzodiazepine hypnotic (marketed as Lunesta), and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant (marketed as Prozac). This combination has been studied for the treatment of patients with insomnia coexisting with major depressive disorder. Eszopiclone acts primarily by modulating the gamma-aminobutyric acid receptor subunit alpha-1 to promote sleep onset and maintenance[2]. Fluoxetine increases synaptic serotonin levels by inhibiting its reuptake, thereby exerting antidepressant effects[6]. Clinical studies have shown that this combination can result in rapid and sustained improvement in sleep parameters, faster onset of antidepressant response, and greater magnitude of antidepressant effect compared to monotherapy. The regimen is generally well tolerated but may increase the risk of central nervous system depression due to additive sedative effects[1][3][5].
- Brand names
- Lunesta + Prozac
- Other names
- eszopiclone and fluoxetineeszopiclone/fluoxetine co-therapy
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on eszopiclone + fluoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eszopiclone + fluoxetine.